Feels that way some times, gotta keep in mind (as far as I know) this company has 7 employees. At the very least 400k per quarter for a phase 3 biotech is incredibly impressive. Also keeping in mind they listed in 2019, finished their phase 2 with great results during 2020 and have been planning a fairly complicated phase 3 for about a year now, no easy feat. In any event I should stop posting about it too and just let them get on with it!
IXC Price at posting:
60.0¢ Sentiment: None Disclosure: Held
